CAR T Cells in Solid Tumors: Current State and Future Direction

Dear Colleagues,

CAR T-cell therapy has achieved unprecedented clinical responses against certain advanced and treatment refractory B lymphocyte malignancies, leading to first regulatory approval of CD19-directed CAR-T cells in 2018. Non-hematological solid tumors, however, have proven less responsive to CAR T-cells, and cross-reactivity against healthy tissues is an important safety issue. Limited homing, along with barriers imposed by the stroma, can restrict the number of CAR-T cells reaching the solid tumor bed. Moreover, a range of obstacles, including limited oxygen and nutrients, as well as the presence of suppressive immune infiltrate, can lead to CAR-T cell anergy or exhaustion. This Special Issue aims to provide the current status of CAR T cells in the treatment of solid tumors, as well cutting-edge cell culture, CAR-design, gene-engineering, and combinatorial approaches for overcoming challenges in the field.

Prof. Dr. Arjan Griffioen
Dr. Melita Irving
Prof. George Coukos
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• CAR T cells
• solid tumors
• combination therapy
• checkpoint inhibitors